Zhixiang Jintai (688443.SH): Marketing application for Telikibart injection for chronic rhinosinusitis with nasal polyps accepted

Zhitong Finance APP News, Zhixiang Jintai (688443.SH) announced that recently, the company's Telikibart Injection (GR1802 Injection) for the indication of chronic rhinosinusitis with nasal polyps in Phase III clinical trials reached the primary endpoint. The company submitted a new drug application for this indication to the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) and the application has been accepted.